Gray zone lymphoma

How might gray zone lymphoma be treated?

Gray zone lymphoma shares features with two other types of lymphoma, classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL). Because these lymphomas are treated differently, the optimal therapy for gray zone lymphoma is unclear. Because there are no consensus guidelines for the best treatment of gray zone lymphoma, treatment is currently determined based on each individual's diagnosis. In general, treatment usually involves chemotherapy (with the specific drugs depending upon each person's treatment plan), which may be followed by radiation therapy in some cases. Some research has suggested that treatment with DLBCL- based regimens is the most effective for some people (such as the drug combination R-CHOP or dose-adjusted EPOCH-R), but additional research is needed. Individual case reports have reported success with different PD-1 inhibitors (such as pembrolizumab and nivolumab), but larger studies are needed to determine if this might be an effective new strategy for treating gray zone lymphoma.

Last updated on 05-01-20

Name: Lymphoma Research Foundation Wall Street Plaza 88 Pine Street, Suite 2400
New York, NY, 10005, United States
Phone: +1-212-349-2910 Toll Free: 1-800-500-9976 Fax : +1-212-349-2886 Email: helpline@lymphoma.org Url: https://www.lymphoma.org/
Name: Leukemia and Lymphoma Society 3 International Drive, Suite 200
Rye Brook, NY, 10573, United States
Phone: 1-(888) 557-7177 (general) Toll Free: 1-(800) 955-4572 (patients and families) Email: https://www.lls.org/content/contact-us Url: https://www.lls.org/

Note, these links are external searches against the National Laboratory of Medicine's drug database. You may need to adjust the search if there are no results found.

Drug Name Generic Name
Imbruvica ibrutinib

Connect with other users with Gray zone lymphoma on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App